The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Status
Conditions
Treatments
Details and patient eligibility
About
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
Full description
Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established testing indications. All genetic tests have risks and possible benefits. The ACT study evaluates the population demographics, reasons for testing, and outcomes through a confidential testing program. Co-morbidities of alpha-1 antitrypsin deficiency other than lung and liver disease are being investigated. Concerns about genetic confidentiality are lessened in this study by a coded testing procedure that returns results through the mail to study participants.
Enrollment
Sex
Volunteers
Inclusion criteria
- Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of symptoms or family genetic risk.
Exclusion criteria
- Any person who has already had genotype and AAT level testing completed and has a qualified result.
Trial contacts and locations
Loading...
Central trial contact
Michelle Owens, RN, BSN; Allison Faunce, B.A.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal